News

Video

ASCENT Study: Impact of Sacituzumab Govitecan on Metastatic TNBC

Shay Elkins, a patient with metastatic triple-negative breast cancer, discussed her experience with second-line treatment. Dr. Noor provided insights into the positive outcomes from the ASCENT study.

Related Videos
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
1 expert is featured in this series.
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.